Oragenics Inc. (NASDAQ: OGEN) stock shows a gain of 13.57% in the current market trading session followed by no recent news regarding the rise of OGEN stock price. Oragenics focuses on the development of Terra CoV-2 vaccine to fight against the ongoing corona virus pandemic and also towards making efficient treatments for novel antibiotics against any infectious disease.
On March 9, Oragenics announced that they have signed a material transfer agreement with Biodextris Inc. The purpose of the agreement is the use of three intranasal mucosal adjuvants in Terra CoV-2 vaccine introduced by OGEN for the treatment of COVID-19. To increase the efficiency of vaccines, Adjuvants are being added in them. BDX100, BDX300, and BDX301 are proteosome-based adjuvants made up of proteins and lipopolysaccharides that have boosted immune response, company productivity, and the ability to administer vaccines through intranasal ways.
The three intranasal adjuvants will be used in conjunction with Oragenics’ antigen vaccine candidate in the preclinical immunological assessment of Terra CoV-2 for the risk reduction of coronavirus disease caused by an infection with the SARS-CoV-2 virus, according to the initial deal. It was also mentioned that the information that has been gathered through the studies after the implication of new intranasal vaccine candidate would be a support for U.S Food and Drug Administration FDA Investigational new drug application and also an application for Health Canada to start clinical trials.
It has been clarified in the agreement that Terra CoV-2 vaccine combined with Biodextris intranasal mucosal adjuvants will be under study in the following studies which are required for approval before testing the vaccine on humans.
- preclinical animal studies
- hamster viral challenge studies
- mouse immunogenicity studies
- rodent toxicology study
Keeping this recent development in the account, it is possible that OGEN stock price is rising after this news.